As of Dec 15
| +4.39 / +1.36%|
The 30 analysts offering 12-month price forecasts for Biogen have a median target of 354.50, with a high estimate of 430.00 and a low estimate of 279.00. The median estimate represents a +8.10% increase from the last price of 327.94.
The current consensus among 34 polled investment analysts is to Buy stock in Biogen. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.